3,840 Shares in Jazz Pharmaceuticals PLC $JAZZ Bought by United Services Automobile Association

Key Points

• The United Services Automobile Association acquired 3,840 shares of Jazz Pharmaceuticals PLC, valued at approximately $472,000.
• Institutional investors and hedge funds now own 89.14% of Jazz Pharmaceuticals' stock, indicating strong interest from major financial players.
• Jazz Pharmaceuticals reported a quarterly loss of ($8.25) earnings per share, missing analysts' expectations, while also achieving revenue of $1.05 billion.

United Services Automobile Association acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,840 shares of the specialty pharmaceutical company's stock, valued at approximately $472,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Versant Capital Management Inc lifted its stake in shares of Jazz Pharmaceuticals by 9.4% in the first quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company's stock valued at $131,000 after purchasing an additional 91 shares during the period. Kendall Capital Management lifted its stake in shares of Jazz Pharmaceuticals by 1.2% in the first quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company's stock valued at $989,000 after purchasing an additional 95 shares during the period. Louisiana State Employees Retirement System lifted its stake in shares of Jazz Pharmaceuticals by 0.6% in the first quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company's stock valued at $2,098,000 after purchasing an additional 100 shares during the period. Sound View Wealth Advisors Group LLC increased its holdings in Jazz Pharmaceuticals by 1.3% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 8,425 shares of the specialty pharmaceutical company's stock valued at $1,046,000 after acquiring an additional 110 shares in the last quarter. Finally, Cardinal Capital Management raised its position in Jazz Pharmaceuticals by 0.9% during the first quarter. Cardinal Capital Management now owns 13,254 shares of the specialty pharmaceutical company's stock worth $1,645,000 after acquiring an additional 114 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ JAZZ traded up $0.38 during trading on Tuesday, reaching $125.60. 169,306 shares of the stock were exchanged, compared to its average volume of 931,080. The business's 50-day moving average price is $118.95 and its 200 day moving average price is $116.22. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The company has a market capitalization of $7.62 billion, a price-to-earnings ratio of -18.66, a price-to-earnings-growth ratio of 7.82 and a beta of 0.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the firm posted $5.30 earnings per share. The company's revenue for the quarter was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, equities analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on JAZZ. The Goldman Sachs Group lifted their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a research report on Friday, August 29th. Zacks Research upgraded shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Deutsche Bank Aktiengesellschaft started coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a "buy" rating and a $152.00 target price for the company. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Finally, Truist Financial lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a "buy" rating in a report on Thursday, August 28th. Fourteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $178.67.

Insider Activity

In related news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the sale, the director owned 429,973 shares in the company, valued at approximately $55,303,127.26. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.